enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026
enGene Holdings reported a 62% complete response rate at 6 months in its pivotal Phase 2 LEGEND trial of detalimogene voraplasmid for high-risk, BCG-unresponsive NMIBC with CIS. The company enrolled 125 patients, above target. Shares surged as much as 62% pre-market after the update. Safety data showed 42% of patients had treatment-related adverse events, mostly mild.
